BOSTON, Dec. 3 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) today issued a review on Arbios Systems, Inc. (OTC Bulletin Board: ABOS - News) entitled: "A New Tool for Rescuing Patients who''s Livers Are Failing." The analyst research review is available on Scimitar''s website:
Arbios Systems, Inc. is developing proprietary medical devices and cell- based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET(TM) Liver Assist Device, a novel blood purification therapy that provides enhanced "liver dialysis," and the HepatAssist(TM) Cell-Based Liver Support System, a bioartificial liver that combines blood detoxification with liver cell therapy to replace whole liver function in patients with the most severe forms of liver failure. For more information on Arbios, please visit
Scimitar Equity Research, Inc. provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about (OTC Bulletin Board: ABOS - News) No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: firstname.lastname@example.org
Source: Scimitar Equity Research, Inc.